Alendronate Sodium Tablet
Product Images NDC 50090-5474

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 50090-5474). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Alendronate Fig1)

FDA Label Image

Figure 2 (Alendronate Fig2)

FDA Label Image

Figure 3 (Alendronate Fig3)

This appears to be a chart showing the mean percent change from baseline in lumbar spine bone mineral density (BMD) in postmenopausal women treated with alendronate 10 mg/day versus placebo over a period of 36 months. The study is a multinational study, and the chart shows the effect of the treatment over time, with months plotted along the x-axis and the percent change in BMD plotted along the y-axis.*

FDA Label Image

Figure 4 (Alendronate Fig4)

FDA Label Image

Studies In Glucocorticoid (Treated Patients Increase in BMD Alendronate 5 mg/day at One Year)

FDA Label Image

Studies In Paget's Disease Of Bone Effect On Serum Alkaline Phosphatase Of Alendronate 40 mg/day Versus Placebo Or Etidronate 400 mg/day (Alendronate Fig6)

The text provides information on the effect of Alendronate 40mg/day on serum alkaline phosphatase in Paget’s disease of bone compared to Placebo or Etidronate 400mg/day through a multinational and US study conducted over a period of 6 months. It also shows a mean % change from Baseline.*

FDA Label Image

Chemical Structure (Alendronate Str)

FDA Label Image

Label Image (Lbl500905474)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.